

Christoph Sarrazin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10728371/publications.pdf>

Version: 2024-02-01

233
papers

18,928
citations

17440

63
h-index

12272

133
g-index

248
all docs

248
docs citations

248
times ranked

15387
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	2.0	14
2	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	4.9	10
3	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
4	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C Registry. <i>Hepatology Communications</i> , 2022, 6, 2488-2495.	4.3	6
5	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. <i>Journal of Hepatology</i> , 2021, 74, 801-810.	3.7	26
6	Point ShearWave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver-Related Events in Patients With Chronic Viral Hepatitis. <i>Hepatology Communications</i> , 2021, 5, 112-121.	4.3	3
7	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 ³ Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	4.4	12
8	Not uncommon: HBV genotype G infections among healthy European HBV carriers with genotype A and E infection. <i>Liver International</i> , 2021, 41, 1278-1289.	3.9	3
9	Treatment failure with DAA therapy: Importance of resistance. <i>Journal of Hepatology</i> , 2021, 74, 1472-1482.	3.7	55
10	Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. <i>Health Science Reports</i> , 2021, 4, e290.	1.5	8
11	Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals: Data from the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1660-1664.	2.0	2
12	Reply to: "Glecaprevir/pibrentasvir+ sofosbuvir+ ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". <i>Journal of Hepatology</i> , 2021, 75, 254-255.	3.7	1
13	Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1604-1613.	2.0	11
14	Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101031.	3.4	2
15	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	3.0	13
16	Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 341-351.	0.5	5
17	Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. <i>Journal of Viral Hepatitis</i> , 2020, 27, 974-986.	2.0	12
18	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. <i>Liver International</i> , 2020, 40, 2660-2671.	3.9	2

#	ARTICLE	IF	CITATIONS
19	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy—Results from the German Hepatitis C Registry. <i>Journal of Viral Hepatitis</i> , 2020, 27, 690-698.	2.0	24
20	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , 2020, 5, .	5.0	2
21	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 841-846.	0.5	4
22	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
23	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 889-899.	3.7	52
24	Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. <i>Virus Evolution</i> , 2019, 5, vez041.	4.9	5
25	Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. <i>Liver International</i> , 2019, 39, 2174-2183.	3.9	17
26	PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure. <i>Journal of Hepatology</i> , 2019, 70, e111.	3.7	3
27	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	5
28	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. <i>Hepatology</i> , 2019, 70, 771-787.	7.3	46
29	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. <i>PLoS ONE</i> , 2019, 14, e0224751.	2.5	1
30	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019, 8, 2101.	2.4	5
31	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. <i>Journal of Hepatology</i> , 2019, 70, 603-614.	3.7	9
32	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen. <i>Antiviral Therapy</i> , 2018, 23, 211-217.	1.0	53
33	Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 114-123.	4.0	37
34	Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. <i>Liver Cancer</i> , 2018, 7, 190-204.	7.7	28
35	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 524-530.	1.7	7
36	Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	1.3	132

#	ARTICLE	IF	CITATIONS
37	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
38	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. <i>United European Gastroenterology Journal</i> , 2018, 6, 213-224.	3.8	22
39	Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection. <i>PLoS ONE</i> , 2018, 13, e0207293.	2.5	6
40	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	8.1	43
41	Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. <i>Clinical and Experimental Hepatology</i> , 2018, 4, 83-90.	1.3	7
42	Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients. <i>Liver International</i> , 2018, 38, 1906-1910.	3.9	18
43	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. <i>Journal of Hepatology</i> , 2018, 69, 1221-1230.	3.7	50
44	Treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , 2018, 69, 544-546.	3.7	3
45	Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 142-151.	2.5	12
46	Early occurrence of hepatocellular carcinoma in patients with and without cirrhosis after HCV treatment with direct-acting antivirals. <i>Journal of Clinical Oncology</i> , 2018, 36, 356-356.	1.6	2
47	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
48	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1131-1139.	3.9	15
49	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. <i>Gut</i> , 2017, 66, 1829-1837.	12.1	24
50	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , 2017, 245, 14-18.	2.1	32
51	Protease Inhibitor Resistance. , 2017, , 21-40.		0
52	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017, 67, 237-245.	3.7	26
53	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 609-618.	3.2	10
54	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017, 67, 680-686.	3.7	37

#	ARTICLE	IF	CITATIONS
55	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. <i>Liver International</i> , 2017, 37, 205-211.	3.9	37
56	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. <i>PLoS ONE</i> , 2017, 12, e0168713.	2.5	6
57	Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels. <i>International Journal of Molecular Sciences</i> , 2016, 17, 922.	4.1	16
58	HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. <i>Clinical and Experimental Gastroenterology</i> , 2016, Volume 9, 351-363.	2.3	3
59	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. <i>PLoS ONE</i> , 2016, 11, e0168544.	2.5	2
60	Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of <i>ε</i> 4 in the course of hepatitis C virus infection. <i>Liver International</i> , 2016, 36, 1267-1274.	3.9	29
61	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. <i>Hepatology</i> , 2016, 63, 63-73.	7.3	50
62	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016, 65, 473-482.	3.7	64
63	Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". <i>Journal of Hepatology</i> , 2016, 65, 1059-1060.	3.7	0
64	Management of HCV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 96-104.	1.3	5
65	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. <i>Scientific Reports</i> , 2016, 6, 35410.	3.3	5
66	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir. <i>Gastroenterology</i> , 2016, 151, 501-512.e1.	1.3	192
67	Reply. <i>Hepatology</i> , 2016, 64, 1378-1379.	7.3	0
68	Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. <i>Journal of Hepatology</i> , 2016, 64, 790-799.	3.7	63
69	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	5.8	23
70	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. <i>Journal of Hepatology</i> , 2016, 64, 486-504.	3.7	389
71	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. <i>PLoS ONE</i> , 2016, 11, e0156731.	2.5	5
72	An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). <i>PLoS ONE</i> , 2016, 11, e0158526.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. <i>PLoS ONE</i> , 2016, 11, e0160668.	2.5	5
74	HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. <i>Antiviral Therapy</i> , 2015, 20, 177-183.	1.0	17
75	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>PLoS ONE</i> , 2015, 10, e0134395.	2.5	67
76	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015, 10, e0145622.	2.5	2
77	An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi e HCV RNA Assay. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1264-1269.	3.9	13
78	Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. <i>Antiviral Research</i> , 2015, 116, 10-16.	4.1	103
79	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	3.7	19
80	Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2746-2755.	3.2	13
81	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 285-294.e1.	4.5	5
82	Assessment of Liver Fibrosis with 2-D Shear Wave Elastography in Comparison to Transient Elastography and Acoustic Radiation Force Impulse Imaging in Patients with Chronic Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2350-2359.	1.5	83
83	Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. <i>Journal of Hepatology</i> , 2015, 62, 791-798.	3.7	33
84	No Distal Migration in Unfixed Versus Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2495-2501.	2.3	4
85	Relationship between vitamin D status and response to hepatitis C virus therapy. <i>Hepatology</i> , 2015, 62, 1642-1643.	7.3	2
86	Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. <i>Journal of Clinical Virology</i> , 2015, 72, 133-140.	3.1	7
87	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. <i>Nature Genetics</i> , 2015, 47, 1443-1448.	21.4	435
88	Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. <i>Virology</i> , 2015, 485, 213-222.	2.4	2
89	Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015, 63, 531-532.	3.7	0
90	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. <i>Journal of Virological Methods</i> , 2015, 214, 29-32.	2.1	39

#	ARTICLE	IF	CITATIONS
91	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN- λ 2 induction by efficient MAVS cleavage. <i>Journal of Hepatology</i> , 2015, 62, 779-784.	3.7	12
92	Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. <i>Liver International</i> , 2015, 35, 176-183.	3.9	4
93	Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection. <i>Hepatology</i> , 2015, 61, 812-822.	7.3	37
94	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 31-40.	3.7	50
95	Protease Inhibitor Resistance. , 2015, , 1-17.		0
96	Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients. <i>PLoS ONE</i> , 2014, 9, e87974.	2.5	19
97	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. <i>Human Molecular Genetics</i> , 2014, 23, 3883-3890.	2.9	50
98	Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. <i>Journal of Clinical Virology</i> , 2014, 59, 148-155.	3.1	2
99	Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2014, 61, 1247-1252.	3.7	36
100	Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1473-1479.	1.5	0
101	HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. <i>Journal of Hepatology</i> , 2014, 60, 22-29.	3.7	24
102	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. <i>Journal of Hepatology</i> , 2014, 60, 913-919.	3.7	39
103	Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. <i>Antiviral Research</i> , 2014, 105, 64-71.	4.1	85
104	Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2014, 1841, 1012-1020.	2.4	50
105	HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy. <i>Antiviral Therapy</i> , 2014, 19, 559-567.	1.0	32
106	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e94512.	2.5	17
107	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e110857.	2.5	15
108	Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e112592.	2.5	20

#	ARTICLE	IF	CITATIONS
109	The importance of HCV RNA measurement for tailoring treatment duration. <i>Digestive and Liver Disease</i> , 2013, 45, S323-S331.	0.9	14
110	Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. <i>Hepatology</i> , 2013, 58, 1270-1276.	7.3	114
111	Long-term follow-up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 586-593.	2.4	32
112	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. <i>Digestive and Liver Disease</i> , 2013, 45, 762-768.	0.9	76
113	Characterization of the inhibition of hepatitis C virus entry by <i>in vitro</i> -generated and patient-derived oxidized low-density lipoprotein. <i>Hepatology</i> , 2013, 57, 1716-1724.	7.3	16
114	Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. <i>Journal of Clinical Microbiology</i> , 2013, 51, 571-577.	3.9	60
115	Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>Journal of Virology</i> , 2013, 87, 6172-6181.	3.4	88
116	Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 803-811.	1.0	1
117	Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2013, 8, e77530.	2.5	8
118	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. <i>Annals of Hepatology</i> , 2013, 12, 190-198.	1.5	2
119	Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e71262.	2.5	11
120	Antiviral strategies in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2012, 56, S88-S100.	3.7	261
121	Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis. <i>Liver International</i> , 2012, 32, 852-858.	3.9	75
122	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	3.7	114
123	Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. <i>Journal of Clinical Virology</i> , 2012, 55, 17-22.	3.1	39
124	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. <i>Gastroenterology</i> , 2012, 143, 439-447.e1.	1.3	30
125	The role of resistance in HCV treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 487-503.	2.4	108
126	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. <i>European Journal of Radiology</i> , 2012, 81, 4112-4118.	2.6	156

#	ARTICLE	IF	CITATIONS
127	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60
128	High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. PLoS ONE, 2012, 7, e41206.	2.5	43
129	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 2012, 55, 1700-1710.	7.3	75
130	Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?. Liver International, 2012, 32, 79-87.	3.9	73
131	Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. PLoS ONE, 2012, 7, e30796.	2.5	78
132	Current Standards in the Treatment of Chronic Hepatitis C. Deutsches Arzteblatt International, 2012, 109, 352-8.	0.9	20
133	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. Gastroenterology, 2011, 141, 1656-1664.	1.3	40
134	Benefit of a clipping device in use in intestinal bleeding and intestinal leakage. Gastrointestinal Endoscopy, 2011, 74, 389-397.	1.0	103
135	CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2011, 46, 973-980.	1.5	3
136	Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 2011, 106, 1663-1669.	0.4	171
137	Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. Journal of Clinical Virology, 2011, 52, 133-137.	3.1	90
138	Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. Journal of Clinical Virology, 2011, 52, 204-209.	3.1	13
139	Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology, 2011, 52, 321-327.	3.1	110
140	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of Hepatology, 2011, 54, 415-421.	3.7	202
141	Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology, 2011, 54, 887-893.	3.7	226
142	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology, 2011, 55, 322-327.	3.7	115
143	Viral kinetics for individualized treatment durations. Journal of Hepatology, 2011, 54, 836-837.	3.7	3
144	Reply to "Vitamin D deficiency and HCV chronic infection: What comes first?". Journal of Hepatology, 2011, 55, 945.	3.7	1

#	ARTICLE	IF	CITATIONS
145	Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon- α and the Protease Inhibitors Boceprevir or Telaprevir. <i>Antiviral Therapy</i> , 2011, 16, 695-704.	1.0	11
146	New hepatitis C therapies in clinical development. <i>European Journal of Medical Research</i> , 2011, 16, 303.	2.2	39
147	How to use virological tools for the optimal management of chronic hepatitis C. <i>Liver International</i> , 2011, 31, 3-12.	3.9	19
148	The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. <i>Journal of Gastroenterology</i> , 2011, 46, 1427-1436.	5.1	21
149	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. <i>Hepatology</i> , 2011, 53, 86-95.	7.3	252
150	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	3.4	40
151	Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e26971.	2.5	120
152	Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1111-1114.	5.8	3
153	Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3309-3315.	3.9	30
154	HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1362-1368.	1.5	3
155	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. <i>PLoS Pathogens</i> , 2011, 7, e1002045.	4.7	102
156	Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon- α -2a and ribavirin. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1303-1307.	1.6	26
157	Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. <i>Antiviral Therapy</i> , 2010, 15, 1099-1106.	1.0	21
158	Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 58-65.	2.2	87
159	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. <i>Hepatology</i> , 2010, 51, 73-80.	7.3	303
160	Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. <i>Hepatology</i> , 2010, 51, 1127-1136.	7.3	115
161	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. <i>Hepatology</i> , 2010, 52, 1201-1207.	7.3	63
162	Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. <i>BMC Gastroenterology</i> , 2010, 10, 103.	2.0	117

#	ARTICLE	IF	CITATIONS
163	Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper. <i>Protein Science</i> , 2010, 19, 1327-1336.	7.6	11
164	A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants. <i>PLoS Computational Biology</i> , 2010, 6, e1000745.	3.2	69
165	Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 884-890.	4.4	33
166	Viral Infections by Hepatotropic Viruses. , 2010, , 671-821.		1
167	Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 447-462.	1.3	489
168	Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. <i>Journal of Hepatology</i> , 2010, 52, 832-838.	3.7	50
169	HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. <i>Journal of Hepatology</i> , 2010, 53, 1022-1028.	3.7	12
170	Evaluation of Angiotensinogen c.1-44G>A and p.M268T Variants as Risk Factors for Fibrosis Progression in Chronic Hepatitis C and Liver Diseases of Various Etiologies. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 407-414.	0.7	2
171	Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography. <i>Radiology</i> , 2009, 252, 595-604.	7.3	601
172	Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. <i>Hepatology</i> , 2009, 50, 369-377.	7.3	53
173	Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. <i>Hepatology</i> , 2009, 50, 1709-1718.	7.3	282
174	Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. <i>Hepatology</i> , 2009, 50, 2001-2006.	7.3	228
175	Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX) Tj ETQq1 1 0.784314 rgBT /O Biomedical and Life Sciences, 2009, 877, 4001-4006.	2.3	23
176	Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2009, 9, 847-852.	2.3	11
177	Clinical relevance of the 2â€²â€²5â€²-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. <i>Journal of Hepatology</i> , 2009, 50, 49-58.	3.7	10
178	Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. <i>Liver International</i> , 2008, 28, 1332-1343.	3.9	77
179	Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. <i>Gastroenterology</i> , 2008, 134, 960-974.e8.	1.3	1,314
180	Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. <i>Genome Biology</i> , 2008, 9, R16.	9.6	74

#	ARTICLE	IF	CITATIONS
181	Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2008, 49, 339-345.	3.7	10
182	Treatment predictors of a sustained virologic response in hepatitis B and C. <i>Journal of Hepatology</i> , 2008, 49, 634-651.	3.7	290
183	Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep [®] , [®] /COBAS) Tj ETQq1 1 0,784314 rgBT /Overlock 1	3.1	54
184	Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas) Tj ETQq0 0 0 rgBT /Overlock 1 and Quantification. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3880-3891.	3.9	115
185	Reply to Real-Time Elastography in the Assessment of Liver Fibrosis. <i>American Journal of Roentgenology</i> , 2008, 190, W164-W164.	2.2	1
186	Real-Time Elastography for Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis. <i>American Journal of Roentgenology</i> , 2007, 188, 758-764.	2.2	301
187	Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. <i>Clinical Microbiology Reviews</i> , 2007, 20, 23-38.	13.6	142
188	Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. <i>Gastroenterology</i> , 2007, 132, 1767-1777.	1.3	602
189	Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy. <i>Gastroenterology</i> , 2007, 132, 921-930.	1.3	79
190	SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α -2b for Genotype 1 Nonresponders. <i>Gastroenterology</i> , 2007, 132, 1270-1278.	1.3	307
191	Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. <i>Hepatology</i> , 2007, 46, 631-639.	7.3	378
192	Structural and functional comparison of the non-structural protein 4B in flaviviridae. <i>Journal of Molecular Graphics and Modelling</i> , 2007, 26, 546-557.	2.4	29
193	The hepatitis C virus NS5A protein and response to interferon α : mutational analyses in patients with chronic HCV genotype 3a infection from India. <i>Medical Microbiology and Immunology</i> , 2007, 196, 11-21.	4.8	8
194	Current therapy for hepatitis C. <i>International Journal of Colorectal Disease</i> , 2007, 22, 341-349.	2.2	13
195	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- α 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-316.	1.0	22
196	Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 779-787.	1.0	10
197	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. <i>Gastroenterology</i> , 2006, 130, 1086-1097.	1.3	500
198	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. <i>Hepatology</i> , 2006, 44, 318-325.	7.3	278

#	ARTICLE	IF	CITATIONS
199	Dynamics of CD81 expression on lymphocyte subsets during interferon- α -based antiviral treatment of patients with chronic hepatitis C. <i>Journal of Leukocyte Biology</i> , 2006, 80, 298-308.	3.3	10
200	Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5. <i>Journal of Clinical Microbiology</i> , 2006, 44, 729-737.	3.9	94
201	Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. <i>Antiviral Therapy</i> , 2006, 11, 371-6.	1.0	17
202	Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 507-19.	1.0	20
203	Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061. <i>Antiviral Therapy</i> , 2006, 11, 371-376.	1.0	26
204	Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2006, 11, 507-519.	1.0	35
205	Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. <i>Hepatology Research</i> , 2005, 31, 18-23.	3.4	5
206	Clinical Significance of In Vitro Replication-Enhancing Mutations of the Hepatitis C Virus (HCV) Replicon in Patients with Chronic HCV Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 1710-1719.	4.0	21
207	Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2005, 42, 605-606.	3.7	7
208	GNB3 C825T polymorphism and response to interferon- α /ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. <i>Journal of Hepatology</i> , 2005, 43, 388-393.	3.7	27
209	Hepatitis C virus-related resistance mechanisms to interferon α -based antiviral therapy. <i>Journal of Clinical Virology</i> , 2005, 32, 86-91.	3.1	47
210	Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. <i>Journal of Clinical Virology</i> , 2005, 32, 289-293.	3.1	46
211	Diagnosis of hepatitis C: update 2004. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S88-S93.	2.8	1
212	Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. <i>Hepatology</i> , 2004, 39, 1456-1457.	7.3	37
213	Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2004, 40, 845-852.	3.7	26
214	Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2. <i>Journal of Hepatology</i> , 2004, 40, 993-999.	3.7	391
215	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004, 41, 652-658.	3.7	56
216	Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. <i>Blood</i> , 2004, 104, 1228-1229.	1.4	17

#	ARTICLE	IF	CITATIONS
217	Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. <i>Hepatology</i> , 2003, 37, 600-609.	7.3	247
218	Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. <i>Hepatology</i> , 2003, 38, 1592-1592.	7.3	32
219	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon \pm for chronic hepatitis C. <i>Journal of Hepatology</i> , 2003, 39, 106-111.	3.7	51
220	Mutations within the CD81-binding Sites and Hypervariable Region 2 of the Envelope 2 Protein: Correlation with Treatment Response in Hepatitis C Virus-infected Patients. <i>Journal of Infectious Diseases</i> , 2003, 187, 982-987.	4.0	16
221	Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses. <i>Journal of Virology</i> , 2002, 76, 11079-11090.	3.4	62
222	Virologische und immunologische Grundlagen der Therapie der chronischen HCV-Infektion. <i>Suchttherapie</i> , 2002, 3, S37-S44.	0.1	0
223	Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. <i>Journal of Clinical Virology</i> , 2002, 25, 23-29.	3.1	93
224	Quasispecies Heterogeneity of the Carboxy-Terminal Part of the E2 Gene Including the PePHD and Sensitivity of Hepatitis C Virus 1b Isolates to Antiviral Therapy. <i>Virology</i> , 2001, 289, 150-163.	2.4	39
225	Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon \pm -2a. <i>Journal of Clinical Microbiology</i> , 2001, 39, 2850-2855.	3.9	46
226	Prospective follow-up of patients with GBV-C/HGV infection: Specific mutational patterns, clinical outcome, and genetic diversity. <i>Journal of Medical Virology</i> , 2000, 62, 191-198.	5.0	12
227	Detection of Residual Hepatitis C Virus RNA by Transcription-Mediated Amplification in Patients With Complete Virologic Response According to Polymerase Chain Reaction-based Assays. <i>Hepatology</i> , 2000, 32, 818-823.	7.3	127
228	Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. <i>Hepatology</i> , 2000, 31, 1360-1370.	7.3	62
229	Mutations in the Protein Kinase-binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response. <i>Journal of Infectious Diseases</i> , 2000, 181, 432-441.	4.0	106
230	Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. <i>Journal of Hepatology</i> , 2000, 33, 640-647.	3.7	29
231	Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. <i>Journal of Hepatology</i> , 1999, 30, 1004-1013.	3.7	77
232	Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. <i>Journal of Hepatology</i> , 1998, 29, 29-35.	3.7	67
233	Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. <i>Journal of Hepatology</i> , 1997, 27, 276-283.	3.7	27